- Agreement will enable HGS to generate revenue from available
manufacturing capacity - - Revenue potential from manufacturing alliances, including the alliance with Hospira, could amount to $30-60 million over the next three to four
ROCKVILLE, Md., Sept. 4 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has entered into an exclusive agreement with Hospira, Inc., for manufacturing process development and commercial supply of select Hospira biopharmaceutical products. Financial terms were not disclosed, and specific products were not identified.
"We look forward to using our company's world-class manufacturing facilities, quality systems and process development capabilities to help advance and supply biopharmaceutical products for Hospira. We are pleased to be chosen by a company of Hospira's stature for such an important role," said Curran Simpson, Senior Vice President of Operations, HGS. "The priority focus of HGS continues to be the commercialization of our lead products. Agreements such as the one announced today will produce near-term revenue from available manufacturing capacity. We see potential for $30-60 million in revenue from manufacturing alliances, including this alliance with Hospira, over the next three to four years."
Protein and antibody process development and manufacturing are core HGS
competencies. The Company currently produces several protein and antibody
drugs in two state-of-the-art cGMP-compliant process development and
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved